Sensyne Health plc’s (LON:SENS): Sensyne Health plc, a healthcare technology company, engages in the development and commercialization of clinically validated software in the United Kingdom. With the latest financial year loss of -UK£19.0m and a trailing-twelve month of -UK£18.5m, the UK£51m market-cap alleviates its loss by moving closer towards its target of breakeven. Many investors are wondering the rate at which SENS will turn a profit, with the big question being “when will the company breakeven?” In this article, I will touch on the expectations for SENS’s growth and when analysts expect the company to become profitable.
Check out our latest analysis for Sensyne Health
Expectation from Healthcare Services analysts is SENS is on the verge of breakeven. They anticipate the company to incur a final loss in 2022, before generating positive profits of UK£13m in 2023. SENS is therefore projected to breakeven around 3 years from now. In order to meet this breakeven date, I calculated the rate at which SENS must grow year-on-year. It turns out an average annual growth rate of 61% is expected, which signals high confidence from analysts. If this rate turns out to be too aggressive, SENS may become profitable much later than analysts predict.
AIM:SENS Past and Future Earnings, March 20th 2020
I’m not going to go through company-specific developments for SENS given that this is a high-level summary, however, bear in mind that by and large healthcare tech companies, depending on the stage of product development, have irregular periods of cash flow. This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments.
Before I wrap up, there’s one aspect worth mentioning. SENS currently has no debt on its balance sheet, which is rare for a loss-making healthcare tech company, which typically has high debt relative to its equity. This means that SENS has been operating purely on its equity investment and has no debt burden. This aspect reduces the risk around investing in the loss-making company.
Next Steps:
There are too many aspects of SENS to cover in one brief article, but the key fundamentals for the company can all be found in one place – SENS’s company page on Simply Wall St. I’ve also put together a list of key aspects you should further research:
- Valuation: What is SENS worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether SENS is currently mispriced by the market.
- Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Sensyne Health’s board and the CEO’s back ground.
- Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
If you spot an error that warrants correction, please contact the editor at [email protected]. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.
We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.
